Patent application number | Description | Published |
20090300864 | Heated Eyelid Cleanser - Embodiments of the invention include a heated eyelid cleansing apparatus, a method of manufacturing a heated eyelid cleansing apparatus, a kit for providing treatment to the eyelids, and a method for cleansing an eyelid with a heated eyelid cleansing composition. The apparatus comprises an eyelid cleansing composition, a fabric pad impregnated with the eyelid cleansing composition, and a heating element. The heating element may be encased within the fabric pad or it may be external to the fabric pad. | 12-10-2009 |
20110020302 | NATURAL PRESERVATIVE BLEND - A composition to be used as a natural preservative is provided. The composition comprises 1.0 to 20% w/w one or more naturally occurring substances containing salicylate, 0.1 to 20% w/w one or more species of lonicera, 0.1 to 80% w/w one or more | 01-27-2011 |
20120201871 | PERMEATION ENHANCERS WITH LIPOSOMES FOR TOPICAL FORMULATIONS - Method for producing liposomes in a composition for skin permeation are provided. A composition that includes water, skin lipids, butters having linoleic acid and linolenic acid, Pracaxi oil, Plukenetia Volubilis seed oil, and phospholipids is provided. The composition is dispersed in a vessel using a high shear homogenizer. Negative pressure is created in the vessel such that liposomes of 5-20 microns are produced thereby providing for increased skin permeation of active ingredients added to the composition. | 08-09-2012 |
20120202882 | PERMEATION ENHANCERS FOR TOPICAL FORMULATIONS - A composition to be used as a permeation enhancer is provided. The composition may be added to topical cosmetics or pharmaceutical formulations that are topically applied. The composition comprises about 0.05-5% w/w of one or more phospholipids, 1-20% w/w of one or more oils having essential fatty acids, behenic acid, and oleic acid, 0.1-3% w/w of one or more skin lipids, and 1-10% w/w of a butter having linoleic acid and linolenic acid. One of the oils used in the composition is Pracaxi oil. | 08-09-2012 |
20120277195 | PERMEATION ENHANCERS FOR TOPICAL FORMULATIONS - A composition to be used as a permeation enhancer is provided. The composition may be added to topical cosmetics or pharmaceutical formulations that are topically applied. The composition comprises about 10-50% of Pracaxi oil, 15-40% of Patauá oil, 10-30% of Inaja oil, and 10-30% of one of more emollients. | 11-01-2012 |
20140371166 | Antibiotic Composition for Inhalation and Irrigation - An antibiotic composition for the treatment of bacterial infections, especially in the respiratory tract is provided. The antibiotic composition may include a mixture of gentamicin as active pharmaceutical ingredient (API), and a micronized poloxamer composition as excipient. Micronized poloxamer composition may be produced by mixing poloxamer 188 and poloxamer 407 in a suitable apparatus where a low-frequency acoustic field may be applied to facilitate mixing. Antibiotic composition may be obtained in powder form, or in solution, and may be administered by inhalation or irrigation. In other embodiments, a topical formulation of the antibiotic inhalation or irrigation composition may be produced. In some embodiments, other suitable poloxamers, or sugar alcohols may be employed as excipients. Due to the synergistic effect of micronized poloxamer composition, antibiotic composition may provide improved solubility and bioavailability of gentamicin, thus decreasing side effects and time of treatment. | 12-18-2014 |
20140371305 | Mupirocin Antibiotic Composition - An antibiotic inhalation or irrigation composition for the treatment of bacterial infections especially in the respiratory tract, is provided. The antibiotic inhalation or irrigation composition may include a mixture of mupirocin as active pharmaceutical ingredient (API), and a micronized poloxamer composition as excipient. Micronized poloxamer composition may be produced by mixing poloxamer 188 and poloxamer 407 in an apparatus where a low-frequency acoustic field is applied to facilitate mixing. Antibiotic inhalation or irrigation composition may be obtained in powder or solution form. In other embodiments, antibiotic inhalation or irrigation composition may be employed to produce a topical formulation for the treatment of traumatic skin lesions. In some embodiments, other suitable poloxamers or sugar alcohols may be employed as excipients. Due to the synergistic effect of micronized poloxamer composition, antibiotic inhalation or irrigation composition may provide improved solubility and bioavailability of mupirocin, thus decreasing side effects and time of treatment. | 12-18-2014 |
20140377355 | Levofloxacin Inhalation Composition - An antibiotic inhalation composition for the treatment of bacteria related diseases in the respiratory tract is provided. The antibiotic inhalation composition may include a mixture of levofloxacin and a micronized poloxamer composition (excipient/solubilizer). Micronized poloxamer composition may include poloxamer 188 and poloxamer 407. The manufacturing method for micronized poloxamer composition may include any suitable process, such as non-contact mixing technology. This technology may include an apparatus for applying low-frequency acoustic field, in order to facilitate the mixing process. Antibiotic inhalation composition may be delivered to the respiratory tract employing any suitable inhalation devices, such as metered-dose inhalers (MDIs), dry powder inhalers, aerosols, syringe, pipette, forceps, measured spoon, eyedropper, nebulizers, or any suitable medically approved delivery apparatus. Furthermore, the synergistic effect of micronized poloxamer composition may provide improved solubility, dispersibility, and bioavailability of any suitable API within the antibiotic inhalation composition; thus, decreasing side effects and time of treatment. | 12-25-2014 |
20140377356 | Inhalation Composition for Treating Respiratory Tract Infections - An inhalation composition for the treatment of bacteria related diseases in the respiratory tract is provided. The inhalation composition may include a mixture of levofloxacin, betamethasone, and a micronized poloxamer composition (excipient/solubilizer). Micronized poloxamer composition may include poloxamer 188 and poloxamer 407. The manufacturing method for micronized poloxamer composition may include any suitable process, such as non-contact mixing technology. This technology may include an apparatus for applying low-frequency acoustic field, in order to facilitate the mixing process. Inhalation composition may be delivered to the respiratory tract employing suitable inhalation devices, such as metered-dose inhalers (MDIs), dry powder inhalers, aerosols, syringe, pipette, forceps, measured spoon, eyedropper, nebulizers, or any suitable medically approved delivery apparatus. Furthermore, the synergistic effect of micronized poloxamer composition may provide improved solubility, dispersibility, and bioavailability of any suitable API within the inhalation composition; thus decreasing side effects and time of treatment. | 12-25-2014 |
20140377357 | Poloxamer Based Inhalation Composition - An inhalation composition for the treatment of bacteria related diseases is provided. The disclosed composition may include a mixture of three or more API(s) and a micronized poloxamer composition. Micronized poloxamer composition may include poloxamer 188 and poloxamer 407. According to an embodiment, an inhalation composition including one or more APIs may be delivered to the respiratory tract by employing inhalation devices, such as inhalers and nebulizers. Antibiotic inhalation composition may provide improved solubility and bioavailability for three or more API(s), such as levofloxacin, betamethasone, and clindamycin. Furthermore, the synergistic effect of micronized poloxamer composition may provide improved solubility and bioavailability of any suitable API. | 12-25-2014 |